Mereo BioPharma Group plc (MREO)

NASDAQ: MREO · Real-Time Price · USD
3.580
+0.090 (2.58%)
Nov 20, 2024, 4:00 PM EST - Market closed
2.58%
Market Cap 554.54M
Revenue (ttm) 1,000,000
Net Income (ttm) -45.32M
Shares Out 154.90M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 727,377
Open 3.470
Previous Close 3.490
Day's Range 3.400 - 3.590
52-Week Range 1.860 - 5.020
Beta 0.97
Analysts Strong Buy
Price Target 7.50 (+109.5%)
Earnings Date Nov 12, 2024

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 33
Stock Exchange NASDAQ
Ticker Symbol MREO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 109.50% from the latest price.

Price Target
$7.5
(109.50% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that...

6 days ago - GlobeNewsWire

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...

8 days ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

2 months ago - GlobeNewsWire

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in ...

3 months ago - GlobeNewsWire

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the ...

5 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

6 months ago - GlobeNewsWire

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its f...

6 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

8 months ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively

8 months ago - GlobeNewsWire

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th...

Other symbols: KRROKRYSTAKWVE
8 months ago - Seeking Alpha

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

9 months ago - GlobeNewsWire

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

11 months ago - GlobeNewsWire

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an up...

1 year ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

1 year ago - GlobeNewsWire

Mereo BioPharma to Present at the Jefferies Healthcare Conference

LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

1 year ago - GlobeNewsWire

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU

1 year ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today a...

1 year ago - GlobeNewsWire

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today ...

2 years ago - GlobeNewsWire

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Mereo to Appoint Four New Directors to its Board of Directors

2 years ago - GlobeNewsWire

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...

2 years ago - GlobeNewsWire